Defensins Attenuate Cytokine Responses Yet Enhance Antibody Responses to Porphyromonas Gingivalis Adhesins in Mice
Overview
Microbiology
Authors
Affiliations
Aim: Our aim is to assess the ability of human neutrophil peptide alpha-defensins (HNPs) and human beta-defensins (HBDs) to attenuate proinflammatory cytokine responses and enhance antibody responses to recombinant hemagglutinin B (rHagB) or recombinant fimbrillin A (rFimA) from Porphyromonas gingivalis 381 in mice.
Materials & Methods: In the first study, C57BL/6 mice were given 10 microg rHagB or rFimA without and with 1 microg HNP1, HNP2, HBD1, HBD2 or HBD3. At 24 h, mice were euthanized and cytokine concentrations were determined in nasal wash fluid (NWF), bronchoalveolar lavage fluids, saliva and serum. In the second study, C57BL/6 mice were given 10 microg rHagB or rFimA without and with 1 microg HNPs or HBDs similarly on days 0, 7 and 14. At 21 days, mice were euthanized and rHagB- and rFimA-specific antibody responses were determined in NWF, bronchoalveolar lavage fluids, saliva and serum.
Results: Mice given rHagB + HNP2, rHagB + HBD1 and rHagB + HBD3 produced significantly lower (p < 0.05) IL-6 responses than mice given rHagB alone. Mice given rHagB + HNP1, rHagB + HNP2, rHagB + HBD1 and rHagB + HBD3 produced significantly lower (p < 0.05) keratinocyte-derived chemokine responses than mice given rHagB alone. Mice given rFimA produced very low levels of IL-6 and only moderate levels of keratinocyte-derived chemokine in NWF that were not attenuated by prior incubation of rFimA with any defensin. Mice given rHagB + HNP1 produced a significantly higher (p < 0.05) serum IgG antibody response than mice given rHagB alone and mice given rFimA + HNP2 produced a higher, but not significant, antibody response.
Conclusion: The ability of HNPs and HBDs to attenuate proinflammatory cytokine responses in murine NWF and enhance IgG antibody responses in serum was dependent upon both the defensin and antigen of P. gingivalis.
Induction of Endogenous Antimicrobial Peptides to Prevent or Treat Oral Infection and Inflammation.
Morio K, Sternowski R, Brogden K Antibiotics (Basel). 2023; 12(2).
PMID: 36830272 PMC: 9952314. DOI: 10.3390/antibiotics12020361.
Peptides in Dentistry: A Scoping Review.
Hardan L, Chedid J, Bourgi R, Cuevas-Suarez C, Lukomska-Szymanska M, Tosco V Bioengineering (Basel). 2023; 10(2).
PMID: 36829708 PMC: 9952573. DOI: 10.3390/bioengineering10020214.
Moazzezy N, Asadi Karam M, Rafati S, Bouzari S, Oloomi M Drug Des Devel Ther. 2020; 14:2797-2807.
PMID: 32764879 PMC: 7381768. DOI: 10.2147/DDDT.S259937.
Xie K, Xie H, Su G, Chen D, Yu B, Mao X Front Immunol. 2019; 10:2333.
PMID: 31636641 PMC: 6787771. DOI: 10.3389/fimmu.2019.02333.
Low concentrations of human neutrophil peptide ameliorate experimental murine colitis.
Maeda T, Sakiyama T, Kanmura S, Hashimoto S, Ibusuki K, Tanoue S Int J Mol Med. 2016; 38(6):1777-1785.
PMID: 27840892 PMC: 5117768. DOI: 10.3892/ijmm.2016.2795.